Ono Pharmaceutical Co., Ltd.

Nobuo Katsube

Tadamitsu Kishimoto

Mitoshi Konno

Mikio Konishi

Ryoichi Ishitani

Narito Tateishi

Kaneyoshi Honjo

A pharmaceutical composition for the treatment and/or prevention of cerebral ischemic diseases, which comprises two components, i.e. an astrocyte function-improving agent, preferably a compound represented by the formula (I): (wherein Ris hydroxy, etc., (1) n is 1, Ris hydrogen and Ris (alkyl of which one carbon atom is substituted by fluorine)-CH&#x2014; or (2) n is 0 or 1, Ris hydrogen, etc., and Ris alkyl, etc.) and a thrombolytic agent, preferably tissue plasminogen activator, as active ingredients. The pharmaceutical composition of the present invention exhibits a synergistic therapeutic effect compared to independent administration of an astrocyte function-improving agent and a thrombolytic agent.

Agent for treatment of cerebral ischemic diseases

Fused thiophone derivatives and drugs containing the same as the active ingredient

Antibody against glyceraldehyde-3-phosphate dehydrogenase and use thereof

Remedies for motor dysfunction and GAPDH expression inhibitors containing as the active ingredient N-&lsqb;3-&lsqb;N-(4-chlorophenylmethyl)carbamoyl&rsqb;propanoyl&rsqb;-L-prolinal. Since it has an effect of ameliorating motor dysfunction, N-&lsqb;3-&lsqb;N-(4-chlorophenylmethyl)carbamoyl&rsqb;propanoyl&rsqb;-L-prolinal is useful in treating motor dysfunction caused by trauma, infection, degeneration, ischemia, tumor, etc. Also, it is useful in treating diseases caused by apoptosis in the cerebellum, spinal nerve nucleus or conduction route due to the overexpression of GAPDH (Parkinson's diseases, Parkinson's syndrome, Huntington's disease, MJD, ALS, CHJ diseases, etc.).

Remedies for motor dysfunction and GAPDH expression inhibitors

Growing community of inventors

Osaka, Japan

Nobuo Katsube